OA 治疗开发中的临床表型、分子内型和治疗类型

IF 29.4 1区医学 Q1 RHEUMATOLOGY

Nature Reviews Rheumatology Pub Date : 2024-05-17 DOI:10.1038/s41584-024-01126-4

Ali Mobasheri, Richard Loeser

引用次数: 0

摘要

了解影响临床表型的分子内型是将骨关节炎（OA）患者分层为治疗亚型的关键一步，有助于开发有针对性的疾病修饰性 OA 药物（DMOADs），以提供真正的长期临床益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Clinical phenotypes, molecular endotypes and theratypes in OA therapeutic development

查看原文本刊更多论文

Clinical phenotypes, molecular endotypes and theratypes in OA therapeutic development

Understanding the molecular endotypes that influence clinical phenotypes is a critical step for the stratification of patients with osteoarthritis (OA) into therapeutic subtypes that can help the development of targeted disease-modifying OA drugs (DMOADs) to provide genuine, long-term clinical benefit.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews Rheumatology 医学-风湿病学

CiteScore

29.90

自引率

0.90%

发文量

137

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Rheumatology is part of the Nature Reviews portfolio of journals. The journal scope covers the entire spectrum of rheumatology research. We ensure that our articles are accessible to the widest possible audience.